Year: 2018
Type: review
Abstract: Immuno-oncology therapies have the potential to revolutionize the armamentarium of available cancer treatments. To further improve clinical response rates, researchers are looking for novel combination regimens, with checkpoint blockade being used as a backbone of the treatment. This Review highlights the significance of small molecules in this approach, which holds promise to provide increased benefit to cancer patients.
Authors: Bayard R. Huck, Lisa Kötzner, Klaus Urbahns
Institution: Merck KGaA, Darmstadt (Germany)
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $5,510
Funders: Merck KGaA, Medicines for Malaria Venture
OpenAlex ID: W2757772966
